Direct intratumoral delivery of Amphiphilic ImmunoModulators (AIM) induces durable anti-tumor efficacy

Elicio Therapeutics Inc. published this content on November 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 06, 2026 at 14:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]